US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback